ATP6V1G3

Across TCGA pan-cancer cohorts, ATP6V1G3 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ATP6V1G3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ATP6V1G3 RNA is repressed in tumor relative to normal tissue. In most cancer types ATP6V1G3 is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

KIRC, KIRP, and UCEC are the cancer types where ATP6V1G3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATP6V1G3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	II,III,IV	−5.239	<.001	12	view →
KIRP	Male	II,III,IV	−5.484	<.001	11	view →
UCEC	All	All	+0.175	.013	4	view →
PRAD	All	All	−0.864	<.001	2	view →
HNSC	All	All	−0.066	.039	2	view →
THCA	All	All	−0.038	.016	2	view →
KICH	Female	II,III,IV	+1.478	.026	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ATP6V1G3–KIRC

Open the KIRC breakdown →